Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Brazil ETF (EWZ) vs Heron Therapeutics Inc (HRTX) Price & Performance

Ishares Msci Brazil ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Ishares Msci Brazil ETF vs Heron Therapeutics Inc — how do they compare? Ishares Msci Brazil ETF trades at $43.01 (market cap $11.30B), while Heron Therapeutics Inc trades at $0.36 (market cap $68.01M). The key difference: Ishares Msci Brazil ETF is far larger — about 166.2× Heron Therapeutics Inc's market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Heron Therapeutics Inc for 35 Days on average.

EWZHRTX
Market Cap
$11.30B$68.01M
Volume
44,036,5971,891,941
Sector
Broad Market / FactorHealth
52-Week High
$43.00$1.49
52-Week Low
$28.79$0.27
Typical Hold Time
50 Days35 Days
Enterprise Value
—$174.75M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Brazil ETF

EWZ, the iShares MSCI Brazil ETF, trades at $42.37, down 1.47% today. The technical outlook is mixed with moving averages signaling bullish momentum but oscillators showing bearish pressure, including overbought RSI readings. Recent news highlights significant investor focus on Brazil's upcoming October election, with unusual options activity and institutional positioning suggesting anticipation of market-moving outcomes. The ETF serves as a key diversifier for U.S. investors seeking exposure to Brazilian equities and commodities.

The outlook for EWZ is heavily tied to Brazilian political and economic developments, particularly the election outcome. While technical indicators show conflicting signals, the substantial options volume and institutional interest indicate heightened expectations for volatility. Key risks include election uncertainty and U.S.-Brazil trade tensions, but potential rate cuts and commodity exposure offer upside for diversified portfolios.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.

While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWZ
98% Buy2% Sell
Avg holding period · 50 Days
HRTX
8% Buy92% Sell
Avg holding period · 35 Days

Top news

Latest headlines on both assets

About Ishares Msci Brazil ETF

EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.

Read more on EWZ →

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX →